# Nova Ltd. (NVMI)

> Source: Nexqual · https://nexqual.com/NVMI · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Nova Ltd. (NVMI), nexqual.com/NVMI" · informational, not investment advice.

**Price:** USD 310.13 (-6.37% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 331.22 · day 305.8–319.49 · 52w 266.43–615.99 · market cap $9.86B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold NVMI (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 12 Form 4 filings, $6.7M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (8 analysts), mean target USD 515.13 (range 415–600).
- Total return with dividends: 1Y -8.9% vs S&P 500 +14.9%; 5Y +199.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 2.77, revenue estimate $282M.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold NVMI. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 0.01% | $729K | New position |

## Insider sales (SEC Form 4, open-market, last ~7 months)
12 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Wolfing Shay | CTO | 3,864 | $1.4M | 15.3% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-01 | Waisman Gabriel | CEO & President | 1,500 | $513K | 5.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-02 | Waisman Gabriel | CEO & President | 2,966 | $1.5M | 9.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22…2026-06-23 | Simon Zehava | Director | 820 | $456K | 29.6% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22…2026-06-23 | Sagiv Sarit | Director | 820 | $456K | 29.6% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22 | Garty Yaniv | Director | 366 | $213K | 15.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22 | Oppenhaim Eitan | Director | 1,290 | $750K | 16.7% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-26 | Oppenhaim Eitan | Director | 1,504 | $781K | 18.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-18 | Sagiv Sarit | Director | 426 | $219K | 14.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-18 | Simon Zehava | Director | 426 | $219K | 14.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-18 | Garty Yaniv | Director | 426 | $219K | 17.3% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-04-02 | Garty Yaniv | Director | 55 | $23K | 2.2% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 8 analysts; mean target USD 515.13 (low 415, high 600).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | Citigroup | Downgrade | Buy → Neutral | $550 → $415 |
| 2026-08-10 | Citigroup | Target lowered | Buy | $595 → $550 |
| 2026-08-07 | Needham | Target lowered | Buy | $640 → $570 |
| 2026-08-07 | Evercore ISI Group | Target lowered | Outperform | $600 → $475 |
| 2026-08-07 | Cantor Fitzgerald | Target lowered | Overweight | $600 → $500 |
| 2026-07-06 | Morgan Stanley | Target raised | Equal-Weight | $494 → $540 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -8.9% | +199.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -8.9% | +24.5% |
| Volatility (annualized) | 59.2% | 47.9% |
| Max drawdown | -48.8% (Jun 2026→Oct 2026) | -52.0% (Dec 2021→Oct 2022) |

## Peers (Semiconductor Equipment & Materials)
AMKR (Amkor Technology, Inc.) USD 39.05 -10.70% · ONTO (Onto Innovation Inc.) USD 198.67 -10.57% · FORM (FormFactor, Inc.) USD 95.03 -15.29% · CAMT (Camtek Ltd.) USD 119.48 -10.23% · ENTG (Entegris, Inc.) USD 128.31 -13.12% · Q (Qnity Electronics, Inc.) USD 108.78 -9.48%

## More
Full page: https://nexqual.com/NVMI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in NVMI's own 20-F filed 2026-02-17 (https://www.sec.gov/Archives/edgar/data/1109345/000117891326000504/zk2634307.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Huawei | "introduced restrictions on exporting certain foreign-made items to Huawei and to customers who are suppliers to Huawei, which is a Chinese" |
| Supplier | GARTNER INC (IT) | "in 2026, following a growth of 11% in 2025 (Gartner Forecast Semiconductor Wafer Fab Equipment, Worldwide, Q425 Update, published December" |
| Competitor | ASML (ASML) | "In addition, we compete with process equipment manufacturers, such as ASML" |
| Competitor | Merck (MRK) | "our portfolio in the wafer level packaging and specialty markets, positions us in direct competition with companies such as Merck and" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.77 | $2.68 | +3.6% | $282.1M | 8 |
| Next quarter (ends 2026-12-31) | $3.06 | $3.04 | +0.8% | $304.9M | 8 |
| Current fiscal year (ends 2026-12-31) | $10.67 | $10.46 | +2.0% | $1.08B | 8 |
| Next fiscal year (ends 2027-12-31) | $13.66 | $12.97 | +5.4% | $1.36B | 8 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±14.0%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 62.3% | ±14.0% |
| 2026-12-18 | 56 | 57.4% | ±18.0% |
| 2027-01-15 | 84 | 55.5% | ±21.3% |
| 2027-02-19 | 119 | 57.8% | ±26.3% |
| 2027-05-21 | 210 | 57.3% | ±34.3% |